RYTM

#1076
Rhythm Pharmaceuticals, Inc. - Common Stock
112.5 3 USD
+0.01%
Market Price
Sector: Healthcare
Base: USD
Profit Currency: USD
Daily Range
112.53
112.53
Year Range
74.51
122.20
Daily Change
+0.59%
Monthly Change
+4.56%
6 month change
+24.77%
Year Change
+2.01%
Previous Close
111.8 7
Open
112.5 3
Low
112.5 3
High
112.5 3
Volume
85
Open full chart

Financials

Overview Statement Statistics Documents

2026

Current report, Q3 FY2026
RHYTHM PHARMACEUTICALS, INC. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
RHYTHM PHARMACEUTICALS, INC. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
RHYTHM PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
RHYTHM PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
RHYTHM PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
RHYTHM PHARMACEUTICALS, INC. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
RHYTHM PHARMACEUTICALS, INC. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
RHYTHM PHARMACEUTICALS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
RHYTHM PHARMACEUTICALS, INC. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
RHYTHM PHARMACEUTICALS, INC. current report, Q1 FY2026
8-K

RHYTHM PHARMACEUTICALS, INC. current report, Q1 FY2025

Full document

Rhythm Pharmaceuticals, Inc. - Form 8-K Summary

Business Context and Reporting Period

Rhythm Pharmaceuticals, Inc. (RYTM) filed this Current Report on Form 8-K on March 14, 2025, with the earliest event reported on the same date. The filing addresses the termination of a material definitive agreement with RareStone Group Ltd. and RareStone Medicine (Shenzhen) Co., Ltd.

Key Financial Metrics

This filing does not report standard periodic financial metrics such as revenue, profit, cash flow, or margins. The primary financial impact disclosed is a one-time cash outflow:

  • Termination Payment: The Company agreed to pay $6.3 million as a repayment of a portion of the upfront payment previously made under the License Agreement.
  • Share Repurchase: The Company agreed to return all shares acquired under the original Share Purchase Agreement to RareStone for no additional consideration.

Material Changes

The material change involves the mutual termination of two agreements originally dated December 3, 2021:

  • Exclusive License Agreement: Terminated effective March 14, 2025.
  • Share Purchase Agreement: Terminated effective March 14, 2025.

All rights and obligations under these agreements have ceased. Both parties have mutually discharged and released each other from any claims, demands, or causes of action arising from the agreements.

Outlook, Risks, and Management Commentary

Management issued a press release on March 20, 2025, regarding the termination (furnished as Exhibit 99.1). The filing indicates that the termination resolves all outstanding obligations and potential liabilities between the parties related to the RareStone Agreements. No specific forward-looking guidance or new risk factors were detailed in this specific text beyond the resolution of the prior agreement.

Investor Verification Checklist

  • Verify the impact of the $6.3 million cash outflow on the Company's current liquidity and cash reserves.
  • Confirm the status of the intellectual property rights previously licensed to RareStone and whether they have reverted to Rhythm Pharmaceuticals.
  • Review the press release (Exhibit 99.1) for any additional strategic rationale regarding the termination not included in the 8-K text.
  • Assess whether the termination affects any future revenue projections or partnership strategies in the Chinese market.

News